|Bid||73.00 x 1800|
|Ask||74.99 x 800|
|Day's Range||72.36 - 76.29|
|52 Week Range||56.81 - 80.74|
|Beta (3Y Monthly)||0.88|
|PE Ratio (TTM)||54.84|
|Earnings Date||Apr 16, 2019 - Apr 22, 2019|
|Forward Dividend & Yield||1.28 (1.60%)|
|1y Target Est||82.78|
Abbott Laboratories' earnings and sales topped first-quarter estimates, but the medical products giant retained its prior full-year outlook and Abbott stock slipped at the close Wednesday.
Check out the companies making headlines midday Wednesday:Qualcomm QCOM — Qualcomm surged 12.3%, adding to Tuesday's gains after news broke that the chipmaker reached a settlement with Apple over their royalty dispute , dropping all legal action between the two companies worldwide.
Abbott Laboratories earnings for the first quarter of 2019 have ABT stock down on Wednesday.Source: Open Grid Scheduler Via FlickrAbbott Laboratories reported earnings per share of 63 cents for the first quarter of the year. This is an increase over the company's earnings per share of 59 cents from the same period of the year prior. It also beats out Wall Street's earnings per share estimate of 61 cents for the quarter, but that couldn't keep ABT stock from falling today.The Abbott Laboratories earnings report for the first quarter of 2019 also includes net income of $672 million. This is up from the company's net income of $418 million reported in the first quarter of 2018.InvestorPlace - Stock Market News, Stock Advice & Trading TipsAbbott Laboratories earnings for the first quarter of 2019 have operating income coming in at $739 million. The health care company's operating income reported during the same time last year was $608 million.The most recent Abbott Laboratories earnings report has it bringing in revenue of $7.54 billion. This is better than the company's revenue of $7.39 billion reported in the first quarter of the previous year. It also beats out analysts' revenue estimate of $7.47 billion for the period, but was unable to stop ABT stock from dropping. * 7 Stocks to Buy for Spring Season Growth All of this is good news for Abbott Laboratories, but it's stock is still down today. This may have to do with its 2019 guidance. Despite beating its own estimates for the quarter, the company didn't increases its earnings per share guidance for the year.ABT stock was down 4% as of Wednesday morning. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Stocks to Buy for Spring Season Growth * This Is How You Beat Back a Bear Market * 7 Dental Stocks to Buy That Will Make You Smile As of this writing, William White did not hold a position in any of the aforementioned securities.Compare Brokers The post Abbott Laboratories Earnings: ABT Stock Down After Q1 Beat appeared first on InvestorPlace.
Jeff Jonas of Gabelli talks about a closed-end fund that invests in the health-care and consumer staples sectors.
Abbott Laboratories Inc reported higher-than-expected quarterly profit and sales on surging demand for its glucose monitoring device, but an unchanged forecast along with regulatory uncertainty kept investors on the edge. Healthcare stocks have been under pressure due to concerns over new regulations, more so after U.S. Senator Bernie Sanders unveiled the latest version of his "Medicare-for-All" plan that would eliminate private insurance and shift all Americans to a public healthcare plan. Abbott shares were down 4 percent, with most other major U.S. device makers also down between 1 percent and 2 percent.
were down 2.8% in trading Wednesday despite the drug company and medical device maker reporting first-quarter earnings that topped its own forecast. Analysts polled by FactSet were expecting the company to report earnings of 61 cents per share on revenue of $7.48 billion. "We're right on track with our expectations to start the year," said Abbott's Chairman and CEO Miles D. White.
(Reuters) - Abbott Laboratories Inc reported higher-than-expected first-quarter profit and sales on Wednesday on surging sales of its Freestyle Libre glucose monitoring device and as more of its heart ...
Health care stocks have fallen out of favor due to sector rotation and political pressure. Explore three trading ideas to benefit from falling prices.
Investing.com - UnitedHealth Group fell deeper into the red Wednesday as analysts turned bearish on the stock in the wake of its CEO's warning on political risk.
Abbott reported adjusted earnings of 63 cents per share on revenue of $7.5 billion, a 2% year-over-year increase. Analysts polled by FactSet were expecting the company to report earnings of 61 cents per share on revenue of $7.48 billion. "We're right on track with our expectations to start the year," said Abbott's Chairman and CEO Miles D. White.
Abbott (ABT) delivered earnings and revenue surprises of 3.28% and 0.91%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
Shares of Abbott Laboratories gained 0.8% in premarket trade Wednesday, after the health-care company reported first-quarter earnings that beat expectations, sales that were slightly above and full-year profit guidance that was in line. Net income rose to $1.13 billion, or 38 cents a share, from $1.05 billion, or 23 cents a share, in the year-ago period. Excluding non-recurring items, adjusted EPS rose to 63 cents from 59 cents, above the FactSet consensus of 61 cents. Sales increased 2% to $7.54 billion, topping the FactSet consensus of $7.48 billion. Medical device sales rose 5.5% to $2.90 billion, above the FactSet consensus of $2.88 billion; diagnostic sales edged up 0.2% to $1.84 billion, matching expectations; nutrition sales grew 2.0% to $1.79 billion versus expectations of $1.74 billion; and established pharmaceutical sales fell 4.9% to $992 million, missing expectations of $999.4 million. The company expects adjusted EPS of 79 cents for the second-quarter, surrounding the FactSet consensus of 80 cents, and $3.15 to $3.25 for 2019, compared with expectations of $3.21. The stock has tacked on 5.6% year to date through Tuesday, while the S&P 500 has rallied 16%.
The Abbott Park, Illinois-based company said it had profit of 38 cents per share. Earnings, adjusted for one-time gains and costs, came to 63 cents per share. The results beat Wall Street expectations. ...
Abbott Laboratories Inc reported first-quarter sales ahead of Wall Street expectations on Wednesday, on double digit growth of its Freestyle Libre glucose monitoring device and as more of its heart valves ...
- Sales and EPS growth exceed guidance; projects strong full-year outlook - Long-term growth drivers - including FreeStyle Libre, MitraClip and Alinity - achieved strong double-digit growth - Reported ...
Investing.com - Abbott Labs (NYSE:ABT) reported first quarter earnings that Beat analysts' expectations on Wednesday and revenue that topped forecasts.
The market opportunity for cannabis is enormous. According to Grand View Research, the spending is expected to hit a staggering $146.4 billion in the U.S. by the end of 2025.Nowadays there are more publicly traded companies to play this megatrend, including names like Canopy Growth (NYSE:CGC), Aurora Cannabis (NYSE:ACB), Cronos Group (NASDAQ:CRON), and Tilray (NASDAQ:TLRY). Beyond these stocks' extreme volatility, they also fetch sky-high valuations, with price-to-sales multiples often well over 50x.So, is there way to get exposure to the cannabis opportunity -- but not take on too much risk? Interestingly enough, there is one such stock to consider: AbbVie (NYSE:ABBV). It's a company that rarely pops up on many people's radar screen when it comes to cannabis. After all, it's one of the world's largest traditional pharma operators, with roots going back to 1888. Keep in mind that ABBV stock was spun-off from Abbott Laboratories (NYSE:ABT) in 2013.InvestorPlace - Stock Market News, Stock Advice & Trading TipsSo what does ABBV stock have to do with cannabis? Well, consider that the company has a drug on the market, called Marinol. It is based on a compound known as dronabinol, a synthetic form of THC, which is a natural part of the marijuana plant (that is, cannabis sativa). This is what activates the "high." * 7 High-Risk Stocks With Big Potential Rewards Now Marinol has proven to be effective in dealing with the symptoms of a host of terrible diseases. For example, it helps deal with the nausea from chemotherapy and the weight problems resulting from those who suffer from AIDS.Granted, Marinol is not a blockbuster drug. But then again, it does show the promise of cannabis as a treatment. More importantly, as for AbbVie stock, the drug is an indication of the company's ability to push innovation with alternative treatments. In other words, it would not be a surprise that it will go on to leverage this experience to look at more treatments.What's more, the use of cannabis for medical purposes is certainly a major opportunity. There are already 41 countries that allow for this, whether on a federal or state level. Bottom Line on AbbVie StockGranted, it would not be a good idea to invest in AbbVie stock just because it has a cannabis drug. To be sure, as seen with the latest earnings report, the company does have some problems as it issued disappointing guidance. Since early this year, ABBV stock has sunk from $91 to $81.The nagging issue is the company's most important drug, Humira (this is for the treatment of arthritis, plaque psoriasis, Crohn's disease, and ulcerative colitis). For the most part, the growth is slowing. And yes, there are worries about when the U.S. patent protection comes off in 2023. * 8 Risky Stocks to Watch as Earnings Season Kicks Off Despite all this, I still think there is a bullish case for AbbVie stock. One, the company has a decent roster of drug candidates that could move the needle -- and help make up for a shortfall in Humira. For example, it has several immunology treatments (risankizumab and upadacitinib) that should hit the markets this year. Interestingly enough, when it comes to the pipeline, AbbVie has lots of potential with the cancer market. To this end, its drug Imbruvica is likely to spin-off various treatments for the category.And who knows, perhaps there could be potential from cannabis as well? I think so.In the meantime, AbbVie stock sports a dirt-cheap valuation, with the forward price-to-earnings multiple at only 8.6x. Oh, and the dividend is at 5.15%, making it one of the highest among the major pharma companies.Tom Taulli is the author of High-Profit IPO Strategies, All About Commodities and All About Short Selling. Follow him on Twitter at @ttaulli. As of this writing, he did not hold a position in any of the aforementioned securities. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Internet Stocks to Watch * 7 AI Stocks to Watch with Strong Long-Term Narratives * 10 Dow Jones Stocks Holding the Blue Chip Index Back Compare Brokers The post Is AbbVie Stock An Undiscovered Cannabis Play Waiting For Some Attention? appeared first on InvestorPlace.